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Primary sclerosing cholangitis (PSC) recurs in 15%-25% of patients transplanted for PSC. In the United States, PSC trans-
plant patients are more likely to receive an organ from a living donor (LD) than patients without PSC. Our aims were to (1)
compare risk of PSC recurrence in LD versus deceased donor recipients and (2) identify risk factors for PSC recurrence. There
were 241 living donor liver transplantations (LDLTs) and 65 deceased donor liver transplantation (DDLT) patients trans-
planted between 1998 and 2013 enrolled in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study who were
evaluated. PSC recurrence risk for LDLT and DDLT recipients was compared using Kaplan-Meier survival curves and log-
rank tests. Cox models were used to evaluate PSC risk factors. Overall PSC recurrence probabilities were 8.7% and 22.4% at
5 and 10 years after liver transplantation (LT), respectively. The risk of PSC recurrence was not significantly different for
DDLT versus LDLT recipients (P5 0.36). For DDLT versus LDLT recipients, unadjusted 5- and 10-year PSC recurrence
was 9.4% versus 9.5% and 36.9% versus 21.1%. Higher laboratory Model for End-Stage Liver Disease (MELD) score at LT,
onset of a biliary complication, cholangiocarcinoma, and higher donor age were associated with increased risks of PSC recur-
rence: for MELD (hazard ratio [HR]5 1.06; 95% confidence interval [CI] 1.02-1.10 per MELD point, P5 0.002); for biliary
complication (HR, 2.82; 95% CI, 1.28-6.25; P5 0.01); for cholangiocarcinoma (HR, 3.98; 95% CI, 1.43-11.09; P5 0.008);
for donor age (per 5-years donor age; HR, 1.17; 95% CI, 1.02-1.35; P5 0.02). Factors not significantly associated with PSC
recurrence included the following: first-degree relative donor (P5 0.11), post-LT cytomegalovirus infection (P5 0.38), and
acute rejection (P5 0.22). Risk of recurrent PSC was not significantly different for DDLT and LDLT recipients. Biliary com-
plications, cholangiocarcinoma, MELD, and donor age were significantly associated with risk of PSC recurrence.
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Since the initiation of Model for End-Stage Liver Dis-
ease (MELD) score–based allocation of liver organs in
2002, patients with primary sclerosing cholangitis
(PSC) have been significantly more likely to receive a
living donor liver transplantation (LDLT) when com-
pared with patients without PSC.(1) In fact, since
2002, nearly 15% of transplant recipients with PSC in
the United States received an LDLT, compared with
4% of non-PSC patients, despite PSC patients
Abbreviations: A2ALL, Adult-to-Adult Living Donor Liver Trans-
plantation Cohort Study; ACR, acute cellular rejection; CI, confidence
interval; CMV, cytomegalovirus; DBD, donation after brain death;
DCD, donation after cardiac death; DD, deceased donor; DDLT,
deceased donor liver transplantation; HLA, human leukocyte antigen;
HR, hazard ratio; LD, living donor; LDLT, living donor liver
transplantation; LT, liver transplantation; MELD, Model for End-
Stage Liver Disease; MMF, mycophenolate mofetil; NA, not avail-
able; PSC, primary sclerosing cholangitis; SD, standard deviation.
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comprising only 6% of the population receiving a
deceased donor liver transplantation (DDLT).(1)
Recent data from Japan demonstrated a 25% risk of
recurrent PSC in LDLT recipients, with a significantly
increased risk when the living donor (LD) was a first-
degree relative of the recipient.(2) Additional risk fac-
tors for recurrence included higher MELD scores at
transplant, postoperative cytomegalovirus (CMV)
infections, and early biliary anastomotic complications.
Importantly, in this cohort, recurrent PSC was associ-
ated with a higher risk of graft loss. Despite the poten-
tial risk of recurrent PSC, a recent analysis of all
transplant recipients in the United States showed that,
among transplant recipients with cholestatic liver dis-
ease (PSC or primary biliary cirrhosis), recipients of an
LDLT had significantly higher posttransplant graft
and patient survival compared with those who received
DDLT.(3) Analysis using data from the national
Organ Procurement and Transplantation Network,
which does not collect data on recurrent PSC, showed
superior graft and patient survival among LDLT recip-
ients with PSC, in contrast to the Japanese report that
revealed high PSC recurrence rates and graft loss in
LDLT recipients.
It is of great importance to validate these findings in
a North American cohort, as donor-relatedness is a
potentially modifiable risk factor in 2 ways. First, if the
relationship applies to North American patients,
LDLT recipients with more than 1 potential LD could
be counseled to preferentially accept a nonrelated
donor in order to reduce the risk of posttransplant
PSC recurrence. Second, for those whose only poten-
tial donor is a first-degree relative, consideration of
deferring LDLT and waiting for a DDLT and/or a
potential donor swap might be options. In contrast, if
the risk of recurrent PSC in those who receive a liver
from a first-degree related donor in North America is
much lower, then this issue should not affect donor
selection. Thus, we used data from the only large mul-
ticenter prospective cohort of LDLT in North America,
the Adult-to-Adult Living Donor Liver Transplanta-
tion Cohort Study (A2ALL), to estimate the risk of
recurrent PSC in North American LDLT recipients
and to identify risk factors for recurrence.
Patients and Methods
STUDY POPULATION
Patients in this study underwent transplantation for
PSC between January 1, 1998, and July 31, 2013, at all
centers participating in A2ALL. A2ALL is an observa-
tional cohort study designed to investigate outcomes in
both donors and recipients of adult-to-adult LDLT,
with comparison to DDLT recipients who had an LD
evaluated. A2ALL was carried out in 2 phases:
A2ALL-1 (January 1, 1998 to August 31, 2009, which
included both LDLT and DDLT recipients) and
A2ALL-2 (September 1, 2009 to January 31, 2014,
which continued follow-up of A2ALL-1 LDLT and
DDLT recipients and included new LDLT recipients).
Nine North American centers were involved in each
phase, with 6 centers spanning both phases. This analy-
sis includes patients transplanted for PSC at 1 of the 9
A2ALL-2 centers (8 US centers, 1 Canadian center).
At the 3 new A2ALL-2 centers, non-A2ALL recipi-
ents (both LDLT and DDLT) transplanted for PSC
during the A2ALL-1 time period were included in the
PSC study by waiver of consent if they met the
A2ALL-1 entry criteria of having had at least 1 poten-
tial LD evaluated. Patients in the 3 A2ALL-1 centers
that were not part of A2ALL-2 were not included.
Both retrospective and prospective data were col-
lected as part of A2ALL. The current study required
data in addition to that collected as part of A2ALL.
These data, as well as imaging reports documenting
PSC recurrence and biliary complications, were
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obtained through detailed chart review under a waiver
of consent. Data fields specific to the PSC substudy
included the following: PSC type, inflammatory bowel
disease, colectomy, cholangiocarcinoma, CMV status,
immunosuppression, rejection, surgical technique, and
PSC recurrence. Immunosuppression was at the dis-
cretion of each center. Each center and the data coor-
dinating center had study protocols and consents
approved by the institutional review board prior to col-
lection and analysis of data.
Recurrent PSC, the primary outcome of interest, was
defined using the Graziadei criteria, which require the
following: confirmed diagnosis of PSC prior to trans-
plantation and either cholangiography demonstrating
multiple biliary strictures >90 days after transplantation
or biopsy findings of fibrous cholangitis and/or fibro-
obliterative lesions, in the absence of hepatic artery
thrombosis/stenosis, chronic ductopenic rejection, iso-
lated anastomotic strictures, nonanastomotic strictures
prior to posttransplant day 90, and donor-recipient
blood-type incompatibility.(4) “Biliary complication” was
defined as anastomotic stricture, bile leak, or biliary cast
after transplantation. All data needed to define recurrent
PSC were captured from each center using a standard-
ized data form, with the case definition being adjudicat-
ed by each site’s primary investigator. Secondary
outcomes were graft failure and death. Graft failure was
defined as retransplantation or death.
STATISTICAL METHODS
Study patients were followed from the time of trans-
plant to the time of either death or chart review,
whichever was earliest. Descriptive statistics are given
as means and standard deviations (SDs) for continuous
variables or as frequencies and percentages for categori-
cal variables. Differences between DDLT and LDLT
were compared using t tests for continuous characteris-
tics and chi-square tests for categorical characteristics.
Probabilities of PSC recurrence, retransplant, or death
as the first event were displayed with a cumulative inci-
dence graph using competing risks methods. To spe-
cifically examine PSC recurrence and risk factors
associated with recurrence, we estimated cause-specific
outcomes, censoring at retransplant and death.
Potential factors associated with PSC recurrence
were examined with multivariate Cox regression mod-
els stratified by donor type (DDLT, LDLT). The best
subsets selection method was used to find parsimoni-
ous models. The following covariates were included in
the model selection process: degree of relatedness
between donor and LDLT recipient (first-degree rela-
tive versus all others); time-dependent biliary complica-
tion; immunosuppression; time-dependent rejection
and rejection treatment; recipient age, sex, race, ethnici-
ty, and blood type; MELD score at transplant; PSC
type; pretransplant colectomy; ulcerative colitis; cholan-
giocarcinoma; cold ischemia time; warm ischemia time;
presence of Roux-en-Y anastomosis; number of biliary
anastomoses; and donor age, sex, race, ethnicity, and
blood type. A history of a biliary complication was a
time-dependent covariate, as the complication itself may
have led to an inflammatory cascade, and/or discovery
of recurrent PSC. Because donation by a first-degree
relative has been previously shown to be associated with
PSC recurrence, we forced inclusion of that covariate in
1 model. To examine the association of PSC recurrence
with the outcomes of graft failure and death, Cox
regression models with time-dependent covariates for
PSC recurrence were used.
Statistical analyses were carried out using SAS, ver-
sion 9.4 (SAS Institute, Cary, NC). The cumulative
incidence function was calculated using the comprisk
macro available from the Mayo Clinic.(5) Results with




The characteristics of the PSC study sample are shown
in Table 1 separately for recipients of DDLTs
(n5 65) and LDLTs (LD; n5 242). The distribu-
tions of donor and recipient race and ethnicity were
significantly different between DDLT and LDLT,
with higher percentages of African Americans (9.2%
versus 4.1%) and Hispanics/Latinos (12.3% versus
2.5%) for DDLT compared with LDLT. DDLT
recipients had a higher mean laboratory MELD score
at transplant than LDLT recipients 20.2 versus 14.7,
respectively (P< 0.001). Mean cold and warm ische-
mia times were significantly longer for DDLT than
LDLT grafts. The use of Roux-en-Y type biliary anas-
tomoses were more common in LDLT procedures
than DDLT (90.5% versus 75.4%, P5 0.001).
There were 121 patients treated for 181 episodes of
acute cellular rejection (ACR): 87 LDLT recipients
were treated for 127 episodes, and 34 DDLT recipi-
ents were treated for 54 episodes of ACR. The propor-
tions of patients with ACR was similar between
LDLT and DDLT recipients. Chronic rejection was
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TABLE 1. Characteristics of Study Population
DDLT (n 5 65) LDLT (n 5 242) P Value
Recipient characteristics
Recipient age, years 45.7 (13.8) 44.4 (13.1) 0.45
Female recipient 15 (23.1) 77 (31.8) 0.17
Recipient race 0.01
Asian 1 (1.5) 5 (2.1)
African American 6 (9.2) 10 (4.1)
Native American 0 (0.0) 1 (0.4)
White 47 (72.3) 195 (80.6)
Multiracial 3 (4.6) 0 (0.0)
Unknown 8 (12.3) 31 (12.8)
Recipient ethnicity 0.002
Hispanic/Latino 8 (12.3) 6 (2.5)
Non-Hispanic/non-Latino 43 (66.2) 194 (80.2)
Unknown 14 (21.5) 42 (17.4)
PSC type 0.11
Intrahepatic 25 (38.5) 127 (52.5)
Extrahepatic 1 (1.5) 12 (5.0)
Intrahepatic and extrahepatic 36 (55.4) 96 (39.7)
Small duct 2 (3.1) 3 (1.2)
Unknown 1 (1.5) 4 (1.7)
Laboratory MELD at transplant 20.2 (9.0) 14.7 (7.2) <0.001
Inflammatory bowel disease 0.32
Ulcerative colitis 33 (50.8) 134 (55.4)
Crohn’s disease 8 (12.3) 37 (15.3)
Indeterminate 0 (0.0) 5 (2.1)
None 24 (36.9) 66 (27.3)
Cholangiocarcinoma found at or before transplant 4 (6.2) 22 (9.1) 0.45
Transplant and donor characteristics
Donor age, years 42.5 (19.7) 38.0 (10.2) 0.12
Female donor 26 (40.0) 113 (46.7) 0.34
Donor race <0.001
Asian 1 (1.5) 4 (1.7)
Black 4 (6.1) 9 (3.7)
White 43 (66.2) 214 (88.4)
Unknown 17 (26.2) 15 (6.2)
Donor ethnicity <0.001
Hispanic/Latino 3 (4.6) 5 (2.1)
Non-Hispanic/non-Latino 19 (29.2) 215 (88.8)
Unknown 43 (66.1) 22 (9.1)
LDLT graft type
Right lobe NA 227 (93.8)
Left lobe 12 (4.9)
Left lateral segment 2 (0.8)
Unknown 1 (0.4)
DDLT donor type
Missing 3 (4.6) NA
DBD 60 (92.3)
DCD 2 (3.0)
Donor relationship to recipient
First-degree LDLT NA 120 (49.6)
Other blood relative LDLT 23 (9.5)
Other LDLT 99 (40.9)
Cold ischemia time, minutes 489.3 (170.9) 80.8 (81.2) <0.001
Warm ischemia time, minutes 45.8 (32.8) 36.2 (13.6) 0.03
Type of biliary anastomosis 0.001
All duct-to-duct 16 (24.6) 23 (9.5)
At least 1 Roux-en-Y 49 (75.4) 219 (90.5)
NOTE: Data are given as mean (SD) or n (%).
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also similar between LDLT and DDLT recipients
(4.5%, respectively).
There were 26 patients diagnosed with cholangiocar-
cinoma at (n5 6) or before (n5 20) transplant. Of
these, 5 (19.2%) had recurrence of cholangiocarcinoma.
Among these 5, 1 had PSC recurrence 2.25 years after
transplant, and all 5 died at a median of 2.4 years.
OVERALL OUTCOMES
Median follow-up time was 5 years, and maximum
follow-up time was 15 years. The cumulative inci-
dence of death, retransplant, and PSC recurrence is
shown in Fig. 1. Fifty-four percent of retransplants
were performed within 3 months of the primary
transplant. PSC recurrence tended to occur later after
transplant; only 1 recurrence was observed within 1
year after transplant. The respective cumulative inci-
dences at 1, 3, 5, and 10 years were 1.6%, 2.5%, 3.0%,
and 3.0% for death; 5.4%, 5.8%, 5.8%, and 7.5% for
retransplant; and 0.3%, 4.0%, 8.7%, and 22.4% for
PSC recurrence. Recurrence-free survival probabilities
(alive with original graft and no PSC recurrence) at 1, 3,
5, and 10 years were 92.7%, 87.7%, 82.5%, and 67.0%,
respectively.
PSC RECURRENCE BY DONOR
TYPE
Overall, there were 34 recorded patients of recurrent
PSC in the study group, 24 in LDLT recipients, and
10 in DDLT recipients. The diagnosis of recurrence
was made by contrast cholangiography in 8, by com-
puted tomography or magnetic resonance imaging in
14, and by histology in 15 (3 patients were diagnosed
with 2 methods). Time to PSC recurrence, censored at
retransplant or death, is shown by group in Fig. 2 for
DDLT, first-degree relative LDLT, and other LDLT.
There was no significant difference in recurrence rate
among the 3 groups (log-rank P5 0.36), between all
LDLT recipients compared with DDLT recipients
(P5 0.36), or between first-degree relative and other
LDLT (P5 0.25).
RISK FACTORS FOR PSC
RECURRENCE (UNIVARIATE
MODELS)
In univariate models, PSC recurrence was significantly
associated with the time-dependent onset of a biliary
complication, including stricture, leak, or biliary cast
(hazard ratio [HR], 2.69; 95% confidence interval
[CI], 1.23-5.85; P5 0.01), the presence of cholangio-
carcinoma (HR, 3.27; 95% CI, 1.24-8.62; P5 0.02),
higher MELD at transplantation (HR, 1.04 per point;
95% CI, 1.00-1.08; P5 0.04), and donor age (HR,
1.16 per 5 years; 95% CI, 1.02-1.32; P5 0.02; Table 2).
RISK FACTORS FOR PSC
RECURRENCE (MULTIVARIATE
MODELS)
Multivariate Cox regression using best subset selection
was performed to identify risk factors for
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FIG. 1. Overall risk of PSC recurrence, death, and retransplant
for LT recipients with PSC, based on the cumulative incidence
function (n5 307).
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FIG. 2. Probability of PSC recurrence by DDLT, first-degree
relative donors, and nonfirst-degree relative donors (censored at
graft failure).
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posttransplant PSC recurrence in liver transplantation
(LT) recipients. A parsimonious 4-variable model
demonstrated that time-dependent onset of a biliary
complication, higher MELD scores at transplant,
higher donor age, and the presence of pretransplant
cholangiocarcinoma had statistically significant asso-
ciations with higher risk of PSC recurrence (Table 2).
To test whether the degree of donor-relatedness was
associated with PSC recurrence, we added a covariate
for first-degree related donor to the model specified
above. The estimated HR for first-degree relative was
1.99 (95% CI, 0.86-4.64) compared with other
LDLT recipients, but this result was not statistically
significant (P5 0.11). Adding the first-degree related
donor term to the model resulted in only very small
changes to the parameter estimates for the other fac-
tors in the model.
RISK FACTORS FOR GRAFT
FAILURE AND MORTALITY
(MULTIVARIATE MODELS)
There were 59 graft failures (26 retransplants and 33
deaths) and 43 deaths (10 following retransplant)
recorded during posttransplant follow-up. Multivari-
ate models using time-dependent PSC recurrence as a
predictor of graft failure and death with covariate
selection informed by the best subset method
demonstrated the following risk factors for graft fail-
ure: time-dependent PSC recurrence (HR, 4.16; 95%
CI, 1.75-9.86; P5 0.001), time-dependent biliary
complication (HR, 4.00; 95% CI, 2.17-7.36;
P< 0.001), cholangiocarcinoma diagnosed at or
before transplantation (HR, 4.01; 95% CI, 2.12-7.57;
P< 0.001), laboratory MELD at transplant (HR,
1.03 per point increase; 95% CI, 1.00-1.054;
P5 0.05), and donor age (1.15 per 5 years older; 95%
CI, 1.03-1.27; P5 0.01). Risk factors for death
included time-dependent PSC recurrence (HR, 2.70;
95% CI, 1.01-7.25; P5 0.049), time-dependent bili-
ary complications (HR, 3.21; 95% CI, 1.59-6.50;
P< 0.001), cholangiocarcinoma diagnosed at or
before transplantation (HR, 6.85; 95% CI, 3.44-
13.62; P< 0.001), laboratory MELD at transplant
(HR, 1.03 per point increase; 95% CI, 1.00-1.06;
P5 0.08), and donor age (1.10 per 5 years older; 95%
CI, 0.97-1.24; P5 0.15).
PATIENT AND GRAFT SURVIVAL
AFTER PSC RECURRENCE
For those patients with documented PSC recurrence,
the 5-year unadjusted patient and graft survival proba-
bilities were 66.5% and 56.8%, respectively. There
were no statistically significant survival differences after
PSC recurrence between living donor (LD) and
TABLE 2. Cox Models of Time to PSC Recurrence, Stratified by Donor Type (Living Versus Deceased)
Factor
Single-Factor Models Multivariate Model*
HR 95% CI P Value HR 95% CI P Value
Time-dependent biliary complication 2.69 1.23-5.85 0.01 2.82 1.28-6.25 0.01
Cholangiocarcinoma diagnosed at or before transplant 3.27 1.24-8.62 0.02 3.98 1.43-11.09 0.008
Laboratory MELD at transplant (per point higher) 1.04 1.00-1.08 0.04 1.06 1.02-1.10 0.002
Donor age (per 5 years older) 1.16 1.02-1.32 0.02 1.17 1.02-1.35 0.02
First-degree related donor 1.62 0.71-3.71 0.25
Recipient age (per 5 years older) 0.95 0.82-1.10 0.49
Female donor 0.82 0.41-1.65 0.58
Female recipient 0.49 0.20-1.20 0.12
Donor race nonwhite 1.72 0.41-7.27 0.46
Recipient race nonwhite 1.02 0.24-4.29 0.98
Recipient Hispanic/Latino 0.49 0.07-3.60 0.48
Time-dependent rejection 1.54 0.78-3.05 0.22
Posttransplant CMV 0.39 0.05-2.88 0.38
>1 biliary anastomosis 1.56 0.70-3.46 0.28
Roux-en-Y anastomosis 1.42 0.48-4.21 0.53
Cold ischemia time (per hour) 0.92 0.76-1.11 0.39
Ulcerative colitis or Crohn’s disease 1.00 0.49-2.07 >0.99
Pretransplant colectomy performed 1.02 0.40-2.66 0.96
Steroid 0.60 0.29-1.24 0.17
Sirolimus or everolimus 0.70 0.17-2.93 0.63
Azathioprine or mycophenolate mofetil or mycophenolic acid 1.51 0.77-2.96 0.23
*Covariates for multivariate model were selected based on best subset selection method.
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deceased donor (DD) recipients (Fig. 3) for patient
survival (P5 0.81) or graft survival (P5 0.77).
Discussion
As an immune-mediated liver disease, PSC may be
affected by LT in several ways. The transplanted organ
brings with it innumerable immune features such as cel-
lular antigens, passenger lymphocytes, DNA, and infec-
tious agents. The recipient immune system, including the
presence of inflammatory bowel disease, prior surgery,
prior infection exposure, and sex, may play a role in PSC
recurrence.(6) Transplantation issues, including ischemia
time, immunosuppression, type of biliary anastomosis,
and hepatic artery thrombosis, may potentially affect the
liver allograft.(7) Weism€uller et al.(6) postulated that the
etiopathogenesis of PSC was multifactorial and included
genetics (human leukocyte antigen [HLA]), autoimmu-
nity, and inflammation caused by infectious agents.
Recipients of first-degree relative donor organs may have
increased exposure to these factors. Differences in these
characteristics may exist between LDLT and DDLT
recipients. In this study, we were able to investigate these
characteristics in a large North American cohort of
LDLT and DDLT recipients transplanted for PSC.
In 2007, the first case series examining LDLT out-
comes in 8 PSC patients, as part of a larger report on
LDLT from Tokyo, was published. All received a
related-donor allograft, and 4/8 (50%) had recurrent
PSC after a mean of 3.3 years.(8) In a retrospective,
single-center North American cohort, Kashyap et al.(9)
compared outcomes in 14 LDLT and 44 DDLT
patients transplanted for PSC. The LDLT recurrence
rate was 28% with a mean follow-up of time of
41.56 24.8 months. The DDLT recurrence rate was
16% with a mean follow-up of 57.26 35.9 months
(P5 0.29). Among biologically related donors, the rate
of recurrence was 37%. Retransplantation rates for
LDLT and DDLT were similar (7% versus 20%;
P5 0.25). One-, 3-, and 5-year patient and graft sur-
vivals were also similar in the 2 groups (96%, 90%,
88% and 89%, 83%, 81%, respectively). A 2010 analy-
sis of the United Network for Organ Sharing database,
including 972 recipients of DDLT and 185 recipients
of LDLT for PSC, demonstrated similarly high 1-
and 5-year patient and graft survivals but did not assess
for PSC recurrence.(10)
In our study, we observed 5- and 10-year PSC recur-
rence rates of 9.5% and 21.1%, respectively, for LDLT
recipients. This compares favorably to the Japanese
cohort, which had recurrence rates of 32% at 5 years
and 52% at 10 years.(2) This may be attributable to dif-
fering baseline population characteristics, surgical tech-
nique, or application of the definition of recurrent PSC
to the data set. The risk of PSC recurrence was not sig-
nificantly different in LDLT and DDLT recipients,
and we observed excellent 1-, 3-, and 5-year recurrence-
free survival rates (92.7%, 87.7%, and 82.5%, respective-
ly). In patients with PSC recurrence, 1-, 3-, and 5-year
patient and graft survivals were 94.1%, 85.9%, 66.5%
and 85.0%, 77.3%, 56.8%, respectively. These rates also
compare favorably to the Japanese cohort with recurrent
PSC, who had graft survivals of 54% at 3 years and 39%
at 5 years.(2)
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FIG. 3. (A) Patient and (B) graft survival following recurrence of PSC after LT.
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Factors associated with increased risk of recurrent
PSC after LDLT shared some similarities with the
Japanese study(2): MELD score at the time of trans-
plantation and the occurrence of biliary complications.
In addition, the present study demonstrated that donor
age and cholangiocarcinoma were important recurrence
risk factors. Pretransplant treatment of cholangiocarci-
noma may result in chemotherapy-induced changes in
the native hepatic artery, resulting in secondary scleros-
ing cholangitis in the transplanted liver, making it dif-
ficult to differentiate from recurrent PSC.(11,12)
Interestingly, Egawa et al.(2) found that a first-
degree relationship between donor and recipient was
statistically significant in predicting recurrence of
PSC with an HR of 2.61. In the present study,
although we noted a trend in the same direction, the
HR of 1.99 for this association was not statistically
significant. We investigated this further by excluding
donor age from the model (LDLT donor age was 35
compared with DDLT donor age 42, P< 0.001) and
still did not find a significant result (HR, 1.60;
P5 0.27). Another possible explanation for the dis-
crepant finding between the 2 studies may be a differ-
ence in definition of first-degree relative. The
Japanese study limited first-degree relatives to the
parent/child relationship, whereas the present study
also included sibling donors. Application of the Japa-
nese definition of first-degree relative to the present
study data yielded an HR of 1.52 and P5 0.39 in our
patient population. Similarly, applying the present
study’s definition of first-degree relative, but using
the Japanese study’s significant variables, the HR for
first-degree relative was 1.68 and the P value was
0.22. This suggests that expansion or limitation of
the definition of first-degree relative did not alter the
findings of either study. The broader implication is
that the North American and Japanese population
may indeed differ with regard to risk of PSC
recurrence.
Limitations of this study include the modest abso-
lute number of PSC recurrences despite a large cohort.
This may have resulted in underpowering of tests of
the association of first-degree relative with PSC recur-
rence. Additionally, the recipients of DD livers may
not be truly representative of all transplant candidates
on the waiting list. This possibility was explored by
Berg et al.,(13) who found there was no significant dif-
ference in portal hypertensive complications between
those in whom LD was seriously contemplated and
those who did not have a potential LD. Patients with
pretransplant cholangiocarcinoma may have undergone
more intensive posttransplant monitoring, which could
result in a higher chance of discovering PSC recur-
rence. The diagnosis of recurrent PSC was made retro-
spectively by chart review using a standardized form,
which created the potential for missing cases of recur-
rent PSC that were not identified in real-time. How-
ever, given that these LDLT recipients had frequent
laboratory tests, an elevated alkaline phosphatase sug-
gesting the potential for recurrent PSC would be easily
identified, and it is likely that we captured most, if not
all, cases of recurrent PSC. We were unable to collect
adequate HLA data to assess its potential association
with PSC recurrence.
In conclusion, our data do not support the notion
that live donation from a first-degree relative increases
the risk of recurrent PSC. When investigating the
identified risk factors for recurrent PSC, no difference
was seen between the LD and DD recipient groups.
Attempts should be made by transplant centers to
address modifiable pretransplant variables. These
would include transplantation at lower MELD scores
and younger donor age, both of which may be control-
lable with LDLT, and limitation of transplantation for
cholangiocarcinoma to only optimized candidates. In
addition, future studies investigating the observed dif-
ferences between North American and Asian patients
may yield further insight into the pathophysiology of
PSC.
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